MEF2D (BC040949) Human Untagged Clone

CAT#: SC125772

MEF2D (untagged)-Human MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D) (cDNA clone MGC:48824 IMAGE:6044434), complete cds


Reconstitution Protocol

USD 310.00

In Stock*

Size
    • 10 ug

Product Images

Other products for "MEF2D"

Specifications

Product Data
Type Human Untagged Clone
Tag Tag Free
Symbol MEF2D
Synonyms DKFZp686I1536; MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D); MEF2D/DAZAP1 fusion; myocyte enhancer factor 2D; myocyte enhancer factor 2D/deleted in azoospermia associated protein 1 fusion protein; OTTHUMP00000031810
Vector pCMV6-XL5
E. coli Selection Ampicillin (100 ug/mL)
Mammalian Cell Selection None
Sequence Data
>OriGene sequence for BC040949 edited
GGGGCCTGAGACCACCCCTGCCCTAGGCCCAGCTTTCCTGGACTGCCTGCCCCCACAAAC
CAACAGCCCGCCCCCAGGTCCCCTGTCGAAGGTATCCTGCAGACCATGAACTGAGCACTG
TTCCCAGACCGTTCATGAGCACAGTGTAAGGTGTGCCGAGACCCACCACCCAGCGAGCCC
CTCCCCTCCGTAGCACTGAGGACCCCCGGAGAAGATGGGGAGGAAAAAGATTCAGATCCA
GCGAATCACCGACGAGCGGAACCGACAGGTGACTTTCACCAAGCGGAAGTTTGGCCTGAT
GAAGAAGGCGTATGAGCTGAGCGTGCTATGTGACTGCGAGATCGCACTCATCATCTTCAA
CCACTCCAACAAGCTGTTCCAGTACGCCAGCACCGACATGGACAAGGTGCTGCTCAAGTA
CACGGAGTACAATGAGCCACACGAGAGCCGCACCAACGCCGACATCATCGAGACCCTGAG
GAAGAAGGGCTTCAATGGCTGCGACAGCCCCGAGCCCGACGGGGAGGACTCGCTGGAACA
GAGCCCCCTGCTGGAGGACAAGTACCGACGCGCCAGCGAGGAGCTCGACGGGCTCTTCCG
GCGCTATGGGTCAACTGTCCCGGCCCCCAACTTTGCCATGCCTGTCACGGTGCCCGTGTC
CAATCAGAGCTCACTGCAGTTCAGCAATCCCAGCGGCTCCCTGGTCACCCCTTCCCTGGT
GACATCATCCCTCACGGACCCGCGGCTCCTGTCCCCCCAGCAGCCAGCACTACAGAGGAA
CAGTGTGTCTCCTGGCCTGCCCCAGCGGCCAGCTAGTGCGGGGGCCATGCTGGGGGGTGA
CCTGAACAGTGCTAACGGAGCCTGCCCCAGCCCTGTTGGGAATGGCTACGTCAGTGCTCG
GGCTTCCCCTGGCCTCCTCCCTGTGGCCAATGGCAACAGCCTAAACAAGGTCATCCCTGC
CAAGTCTCCGCCCCCACCTACCCACAGCACCCAGCTTGGAGCCCCCAGCCGCAAGCCCGA
CCTGCGAGTCATCACTTCCCAGGCAGGAAAGGGGTTAATGCATCACTTGAACAATGCCCA
GCGCCTTGGGGTCTCCCAGTCTACTCATTCGCTCACCACCCCAGTGGTTTCTGTGGCAAC
GCCGAGTTTACTCAGCCAGGGCCTCCCCTTCTCTTCCATGCCCACTGCCTACAACACAGA
TTACCAGTTGACCAGTGCAGAGCTCTCCTCCTTACCAGCCTTTAGTTCACCTGGGGGGCT
GTCGCTAGGCAATGTCACTGCCTGGCAACAGCCACAGCAGCCCCAGCAGCCGCAGCAGCC
ACAGCCTCCACAGCAGCAGCCACCGCAGCCACAGCAGCCACAGCCACAGCAGCCTCAGCA
GCCGCAACAGCCACCTCAGCAACAGTCCCACCTGGTCCCTGTATCTCTCAGCAACCTCAT
CCCGGGCAGCCCCCTGCCCCACGTGGGTGCTGCCCTCACAGTCACCACCCACCCCCACAT
CAGCATCAAGTCAGAACCGGTGTCCCCAAGCCGTGAGCGCAGCCCTGCGCCTCCCCCTCC
AGCTGTGTTCCCAGCTGCCCGCCCTGAGCCTGGCGATGGTCTCAGCAGCCCAGCCGGGGG
ATCCTATGAGACGGGAGACCGGGATGACGGACGGGGGGACTTCGGGCCCACACTGGGCCT
GCTGCGCCCAGCCCCAGAGCCTGAGGCTGAGGGCTCAGCTGTGAAGAGGATGCGGCTTGA
TACCTGGACATTAAAGTGACGATTCCCACTCCCCTCCTCTCAGCCTCCCTGATGAAGAGT
TGACAATCTCACCGCCCGCCCTTCCCTGCCCCGGGCTCCTCCCGCTCGACCCCCACTTCC
TTTCTTGTGCTTCGTGTCCTGTTGACGGTTACATTTGTGTATAATTATTATATTATTATT
ATTATTATTATATTTTTTTTAATTTGGATTCTCGCTTTGGAGAGGGGGATGCTCTCATCC
CCTCTTTCTGTACCCCCCACCATTTTCACTGGCTGGGGGGCTCTCTTTTTCGCGGGAAGG
GGGGACACTTTGCACGTTGTACACATATGCTGCAGGAAGGGGGTGGGGGGCCCAATAAGG
CCTTTGGGAAAGGACAGGTGCCGAGCCCTGCATGTGGAGCCCTCCCACCCCACCCCCAGA
TAGAGGGAAATAACCAAAAAACTACCAAACAACAGAAACCCACACTCTAGACTGAAACCC
CAAAGTGGGCTTGATGGGTGGGTTTGTGTTTCAAGGGGAAAGTGAGGCAGAGGTTCTGAA
AAGGGTCTCTGTTTTTGTGTTCATGTAGCCATAGGCACATGGAGCAGAATACTTAAGCCT
GGCCCCCAAATGCCCCTGCACACACACGTGCCACACCTGCGCTGATTCTTGTGTGTGCTG
CACCCCCAAGGTGTGTGGGTGCTGGCTGAGCTTTGGGCCGGGAAGGCAGCCTGGGAATCT
GAGGCTGGAGACAGGGGTTTGAGGTGGGGGCCTCTCTGGAAGCACATTTGGAGGGAAAGA
CAAGAGAGCCATGAGGAGAGGGCTGAGGAGGGCAGAAGGGCTAGGCAGGGGGCAAATTGA
GCCCCTCCCTTCCCCAGTTTTTCTCTAAGATATACAGTGCAATAGCTCCCCACCCCTCAG
TTGACGCCAGCCCTGTAAAGCTGGCCACAGTGTGCAGGGAGAATGGGGAGAGGGTCTTCA
GTGAGGTGGCTGGGGCGAGAGTCGGCCTGGACTTCCCTGGGGTGCTCCAGGCCAGAGCTC
TTTCATTGGGGCGAGTGTGGTGAGGGGACGTCCTTGGTCTTGCACGCACACTACCTGGGG
GAGTCAACACTGGGATGGTCTGTGGGGTGGGAGGGCCTACGGATGGGTCCGTAGAGGTCC
CACCTCCCTCATTCCTCCTTGGCCCCTCTCCCTAGCTTCTCCTGTTAGCTCCTTCTGCTC
CTGACCCCACCTCCTTGCTCTTGGCGCCCCTATTGTCTCTGGCTACCTCCTTGTCCCACC
ACCTCCAGGCTGCATCCCACCTTCCCTCTTGGCTACTGTAATTGTAAATAGCGACCTTTG
GAAAACGTTAGCGGTGTAACAGTCCAGGAAACTGTTTTTTTTTGTTGTTGTTGTATTGAT
ATGAAATGAGATTCTATTTTTGTCAAAGTATATTGTAATAATAATGACTCAAACGGCCCG
TACTGTACAGACGAAAAAAAAAAAAAAAAA
Restriction Sites NotI-NotI     
ACCN BC040949
Insert Size 3200 bp
OTI Disclaimer Our molecular clone sequence data has been matched to the reference identifier above as a point of reference. Note that the complete sequence of our molecular clones may differ from the sequence published for this corresponding reference, e.g., by representing an alternative RNA splicing form or single nucleotide polymorphism (SNP).
OTI Annotation This TrueClone is provided through our Custom Cloning Process that includes sub-cloning into OriGene's pCMV6 vector and full sequencing to provide a non-variant match to the expected reference without frameshifts, and is delivered as lyophilized plasmid DNA.
Product Components The cDNA clone is shipped in a 2-D bar-coded Matrix tube as dried plasmid DNA. The package also includes 100 pmols of both the corresponding 5' and 3' vector primers in separate vials. Every lot of primer is tested to provide clean sequencing of OriGene TrueClones.
Reconstitution 1. Centrifuge at 5,000xg for 5min.
2. Carefully open the tube and add 100ul of sterile water to dissolve the DNA.
3. Close the tube and incubate for 10 minutes at room temperature.
4. Briefly vortex the tube and then do a quick spin (less than 5000xg) to concentrate the liquid at the bottom.
5. Store the suspended plasmid at -20°C. The DNA is stable for at least one year from date of shipping when stored at -20°C.
Reference Data
RefSeq BC040949.1, AAH40949.1
RefSeq Size 3210 bp
Locus ID 4209
Cytogenetics 1q22
Protein Families Transcription Factors
Gene Summary 'This gene is a member of the myocyte-specific enhancer factor 2 (MEF2) family of transcription factors. Members of this family are involved in control of muscle and neuronal cell differentiation and development, and are regulated by class II histone deacetylases. Fusions of the encoded protein with Deleted in Azoospermia-Associated Protein 1 (DAZAP1) due to a translocation have been found in an acute lymphoblastic leukemia cell line, suggesting a role in leukemogenesis. The encoded protein may also be involved in Parkinson disease and myotonic dystrophy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2012]'

{0} Product Review(s)

0 Product Review(s) Submit review

Be the first one to submit a review

Product Citations

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.